Home › Research › Treatments
Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study
Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction We evaluated lecanemab's safety and cognitive outcomes in Chinese patients with Alzheimer's disease (AD) and the utility of blood-based biomarkers (BBMs) for treatment guidance. Methods A multicenter, real-world cohort enrolled 1042 patients receiving lecanemab, with 453, 359, 97 patients followed up at 3, 6, 12 months, respectively. Safety outcomes included amyloid-related imaging abnormalities (ARIA) and infusion-related reactions (IRRs), and the main clinical outcome was Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score change. Results Of 1,042 patients, ARIA occurred in 7.87%, and IRRs in 16.12%. Discontinuation was 16.51%, mainly due to financial burden. CDR-SB did not change at 12 months overall or in any subgroup. High-accuracy BBMs were the sole AD biomarker assay in 5.28%, with comparable outcomes. Discussion Lecanemab exhibited favorable 12-month safety, with no clear evidence of cognitive decline, and BBMs hold potential for treatment guidance. Further studies using a control group are now warranted.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wu, H., Chen, Q., Fang, M., Tang, H., Liu, H., Liu, J., et al. (2026). Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71702
Vancouver
Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, et al. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.71702. PMID: 42557932.
BibTeX
@article{wu2026-42557932,
author = {Wu, H. and Chen, Q. and Fang, M. and Tang, H. and Liu, H. and Liu, J. and Zhang, J. and Chi, L. and others},
title = {{Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71702},
pmid = {42557932},
url = {https://doi.org/10.1002/alz.71702}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Of 1,042 patients, ARIA occurred in 7.87%, and IRRs in 16.12%.
- CDR-SB did not change at 12 months overall or in any subgroup.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants1,042
- Effect size7.87%; 16.12%; 16.51%
- Evidence strengthModerate
How this study scored 67/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 41 of the 61 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,042 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42557932) |
| Free to read | 2 / 2 | Free to read |
| Points | 41 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 41 of the 61 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “multicenter”
4 studies in the library carry the topic tag “multicenter”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.